Asset profile

Camrelizumab

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. No upcoming registrational readout date is posted to the registry — check News for topline announcements.

How the evidence outlook works ↗

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (3)
December 2026 (3)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2026-12 · NCT07107217 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2026-12-31 · NCT07161791 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06533384 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (6)
March 2027 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03-31 · NCT06632405 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (1)
Phase 2Germline BRCA-mutated HER2-negative Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05576389 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)
Phase 2Triple Negative Breast Cancer (TNBC), Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06 · NCT06731153 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (3)
Phase 2Advanced Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (3)
March 2028 (1)
Phase 2Breast Cancer Triple Negative Breast CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT07471815 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (1)
Phase 2/3Breast CancerRecruiting
Est. primary completion 2028-09-01 · NCT04803539 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)
Phase 3Breast Cancer Stage IV, Triple -Negative Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06889688 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (1)
April 2032 (1)
Phase 1/2Breast NeoplasmsRecruiting
Est. primary completion 2032-04-30 · NCT05981001 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.